tradingkey.logo

Telomir Pharmaceuticals Inc

TELO
查看详细走势图
1.410USD
+0.040+2.92%
收盘 12/19, 16:00美东报价延迟15分钟
47.70M总市值
亏损市盈率 TTM

Telomir Pharmaceuticals Inc

1.410
+0.040+2.92%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+2.92%

5天

-2.76%

1月

+1.44%

6月

-19.89%

今年开始到现在

-65.78%

1年

-72.78%

查看详细走势图

TradingKey Telomir Pharmaceuticals Inc股票评分

单位: USD 更新时间: 2025-12-19

操作建议

Telomir Pharmaceuticals Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在药品行业排名131/158位。机构持股占比非常高,近一月多位分析师给出公司评级为。最高目标价15.50。中期看,股价处于平稳状态。近一个月,市场表现较强,基本面评分较高,但较强的走势得没有得到技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

Telomir Pharmaceuticals Inc评分

相关信息

行业排名
131 / 158
全市场排名
483 / 4582
所属行业
药品

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 0 位分析师
--
评级
15.500
目标均价
+999.29%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Telomir Pharmaceuticals Inc亮点

亮点风险
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
利润高增长
公司净利润处于行业前列,最新年度总收入0.00美元
估值高估
公司最新PE估值-3.85,处于3年历史高位
机构减仓
最新机构持股2.75M股,环比减少26.38%
先锋集团持仓
明星投资者先锋集团持仓,最新持仓市值1.10M

Telomir Pharmaceuticals Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Telomir Pharmaceuticals Inc简介

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
公司代码TELO
公司Telomir Pharmaceuticals Inc
CEOAminov (Erez)
网址https://telomirpharma.com/

常见问题

Telomir Pharmaceuticals Inc(TELO)的当前股价是多少?

Telomir Pharmaceuticals Inc(TELO)的当前股价是 1.410。

Telomir Pharmaceuticals Inc的股票代码是什么?

Telomir Pharmaceuticals Inc的股票代码是TELO。

Telomir Pharmaceuticals Inc股票的52周最高点是多少?

Telomir Pharmaceuticals Inc股票的52周最高点是5.400。

Telomir Pharmaceuticals Inc股票的52周最低点是多少?

Telomir Pharmaceuticals Inc股票的52周最低点是1.120。

Telomir Pharmaceuticals Inc的市值是多少?

Telomir Pharmaceuticals Inc的市值是47.70M。

Telomir Pharmaceuticals Inc的净利润是多少?

Telomir Pharmaceuticals Inc的净利润为-16.53M。

现在Telomir Pharmaceuticals Inc(TELO)的股票是买入、持有还是卖出?

根据分析师评级,Telomir Pharmaceuticals Inc(TELO)的总体评级为--,目标价格为15.500。

Telomir Pharmaceuticals Inc(TELO)股票的每股收益(EPS TTM)是多少

Telomir Pharmaceuticals Inc(TELO)股票的每股收益(EPS TTM)是-0.367。
KeyAI